EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MiR-525-5p inhibits diffuse large B cell lymphoma progression via the Myd88/NF-κB signaling pathway

Xiuchen Guo, Jingbo Zhang, Jingya Zeng, Yiwei Guo, Lina Zhao

PeerJ · 2023

DOI: 10.7717/peerj.16388 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, 2023. Verfasst von Xiuchen Guo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Harbin Medical University Cancer Hospital, Harbin, China. Hauptthemen laut MEDLINE: MicroRNAs, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Life Oasis Public Welfare Service Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse large B-cell lymphoma (DLBCL) is a B-cell lymphoma with a high degree of aggressiveness. Recently, evidence has shown that miR-525-5p is decreased in DLBCL, suggesting its possible involvement in tumor progression. In this study, miR-525-5p suppressed proliferation, invasion and clonogenicity, and increased apoptosis of U2932 cells, whereas miR-525-5p silencing enhanced tumor cell growth. Next, miR-525-5p targets the 3′-UTR of Myd88, and Myd88 protein was increased in lymphoma tissues. Similar to the miR-525-5p mimic, Myd88 siRNA suppressed proliferation, invasion, and clonogenicity, and enhanced apoptosis of U2932 cells. We observed that Myd88 reversed the inhibitory effect of miR-525-5p on tumor cell growth by transfecting cells with miR-525-5p mimics alone or together with Myd88 overexpression vector. In addition, in vivo studies have shown that compared to the control group, U2932 cells with upregulated miR-525-5p expression have a reduced ability to induce tumor formation. In conclusion, our results demonstrate that miR-525-5p inhibits the progression of DLBCL through the Myd88/NF-κB pathway, which largely fills the gap of previous studies, and our results may provide a new reference for the targeted treatment of DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsLymphoma, Large B-Cell, DiffuseHumansNF-kappa BMyeloid Differentiation Factor 88Signal Transduction

Stichwörter der Autor:innen

DLBCLInvasionMiR-525-5pThe Myd88/NF-κB pathway

Substanzen

NF-kappa BMicroRNAsMyeloid Differentiation Factor 88MIRN525 microRNA, human

Autor:innen und Institutionen

  • Department of Hematology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Department of Clinical Laboratory, Harbin Medical University Cancer Hospital, Harbin, China.

Förderung

  • Beijing Life Oasis Public Welfare Service Center

Zitieren

APA

Guo, X., Zhang, J., Zeng, J., Guo, Y., & Zhao, L. (2023). MiR-525-5p inhibits diffuse large B cell lymphoma progression via the Myd88/NF-κB signaling pathway. PeerJ. https://doi.org/10.7717/peerj.16388

Vancouver

Guo X, Zhang J, Zeng J, Guo Y, Zhao L. MiR-525-5p inhibits diffuse large B cell lymphoma progression via the Myd88/NF-κB signaling pathway. PeerJ. 2023. doi:10.7717/peerj.16388

BibTeX
@article{Guo2023,
  author = {Guo, Xiuchen and Zhang, Jingbo and Zeng, Jingya and Guo, Yiwei and Zhao, Lina},
  title = {MiR-525-5p inhibits diffuse large B cell lymphoma progression via the Myd88/NF-κB signaling pathway},
  journal = {PeerJ},
  year = {2023},
  doi = {10.7717/peerj.16388}
}
Kostenlos starten →